- Home
- GGAL vs ALKS Comparison
GGAL vs ALKS Comparison
Compare GGAL & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | ALKS |
|---|---|---|
| Founded | 1905 | 1987 |
| Country | Argentina | Ireland |
| Employees | 10079 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | GGAL | ALKS |
|---|---|---|
| Price | $50.15 | $53.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $69.00 | $43.43 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 03-07-2023 | 05-05-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $62.29 | $24.26 |
| Revenue Next Year | $22.88 | $4.47 |
| P/E Ratio | $13.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.89 | $25.17 |
| 52 Week High | $62.11 | $55.28 |
Technical Indicators
Market Signals| Indicator | GGAL | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 75.53 |
| Support Level | $50.12 | $27.65 |
| Resistance Level | $51.09 | N/A |
| Average True Range (ATR) | 2.10 | 2.10 |
| MACD | -0.65 | 0.48 |
| Stochastic Oscillator | 24.56 | 94.18 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.